biostudies-literatureYang SHMRF344https://www.ebi.ac.uk/biostudies/studies/S-EPMC5437682biostudies-literatureUnknown17(1)<h4>Background</h4>DNA repair pathways are used by cancer cells to overcome many standard anticancer treatments, causing therapy resistance. Here, we investigated the role of XRCC4-like factor (XLF), a core member of the non-homologous end joining (NHEJ) repair pathway, in chemoresistance in hepatocellular carcinoma (HCC).<h4>Methods</h4>qRT-PCR analysis and western blotting were performed to detect expression levels of genes and proteins related to NHEJ. NHEJ repair capacity was assessed in vitro (cell-free) and in vivo by monitoring the activity of the NHEJ pathway. Cell viability and IC50 assays were used to measure sensitivity to drug therapy. A xenograft HCC model was used to develop methods of targeting XLF-induced chemosensitization. Clinicopathological analysis was conducted on patBMC cancerXLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.PMC543768203143396Wang XQYang SfalseXLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.<h4>Background</h4>DNA repair pathways are used by cancer cells to overcome many standard anticancer treatments, causing therapy resistance. Here, we investigated the role of XRCC4-like factor (XLF), a core member of the non-homologous end joining (NHEJ) repair pathway, in chemoresistance in hepatocellular carcinoma (HCC).<h4>Methods</h4>qRT-PCR analysis and western blotting were performed to detect expression levels of genes and proteins related to NHEJ. NHEJ repair capacity was assessed in vitro (cell-free) and in vivo by monitoring the activity of the NHEJ pathway. Cell viability and IC50 assays were used to measure sensitivity to drug therapy. A xenograft HCC model was used to develop methods of targeting XLF-induced chemosensitization. Clinicopathological analysis was conducted on pat2017-01-01T00:00:00Z2017 May2025-04-19T19:07:00.229Z2019-03-27T02:45:26ZS-EPMC54376822852606910.1186/s12885-017-3345-y